Literature DB >> 22704156

Hypoglycaemia: a therapeutic concern in type 2 diabetes.

Alan J Garber1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22704156     DOI： 10.1016/S0140-6736(12)60947-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors.

Authors:  Gerald H Tomkin
Journal:  World J Diabetes       Date:  2014-10-15

2.  A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes.

Authors:  J Hans DeVries; Luigi Meneghini; Anthony H Barnett; Timothy Reid; Marie-Paule Dain; Wolfgang Landgraf; Aleksandra Vlajnic; Louise Traylor; Richard M Bergenstal
Journal:  Eur Endocrinol       Date:  2014-02-28

3.  Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.

Authors:  Jari Haukka; Fabian Hoti; Panu Erästö; Tero Saukkonen; Sari Mäkimattila; Pasi Korhonen
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-10-21       Impact factor: 2.890

4.  Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes.

Authors:  Seamus Sreenan; Marc Andersen; Brian Larsen Thorsted; Michael L Wolden; Marc Evans
Journal:  Diabetes Ther       Date:  2014-07-15       Impact factor: 2.945

Review 5.  Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience.

Authors:  Wing Bun Chan; Jung Fu Chen; Su-Yen Goh; Thi Thanh Huyen Vu; Iris Thiele Isip-Tan; Sony Wibisono Mudjanarko; Shailendra Bajpai; Maria Aileen Mabunay; Pongamorn Bunnag
Journal:  Diabetes Metab Syndr Obes       Date:  2017-12-15       Impact factor: 3.168

6.  Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.

Authors:  K M Dungan; I Raz; Z Skrivanek; W Sealls; J L Fahrbach
Journal:  Diabetes Obes Metab       Date:  2015-11-03       Impact factor: 6.577

7.  Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.

Authors:  Xinhua Xiao; Changjiang Wang; Xiaoyang Lai; Bin Zhang; Liqun Gu; Jianing Hou; Zhiguang Zhou
Journal:  J Diabetes Investig       Date:  2020-01-03       Impact factor: 4.232
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.